Everest Medicines signed an exclusive license agreement with Micot to commercialize MT1013.[1][2][3] The contract covers markets in China, Asia Pacific, excluding Japan.[1][2] The partnership aims to commercialize MT1013 in Greater China and other Asian markets.[2] This gives Everest Medicines a partner to introduce the drug to these markets.[3] The contract was announced in January 2026.[3] MT1013 is the drug targeted by the partnership.[1]